European companies are set to increase their investment in R&D by 5 per cent per annum over the next three years, closing the gap with US counterparts.
European venture capitalists are no longer prepared to take any risk with their investments, undermining the biotech sector. That, anyway, is the opinion of many a frustrated biotech entrepreneur.
Who should profit from cutting-edge academic research: the scientists or the institution that funds them? Both, in a new biotech company launched by one of Sweden’s leading researchers.
It may be that the similarity between the name of a US memory chip supplier, Rambus, and that of a rebel and indomitable hero, Rambo, is purely coincidental. Yet, looking at the story of Rambus, it is difficult to avoid comparisons.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening.
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.